Table 2

Clinical and laboratory measures of the three groups at each visit

MeasuresMTXTwHFMTX+TwHF
0 w4 w12 w24 w0 w4 w12 w24 w0 w4 w12 w24 w
Patient's assessment of pain, mm71.8 (22.5)52.3 (27.0)43.4 (25.7)31.1 (24.4)68.5 (25.5)48.3 (25.6)39.1 (27.8)29.7 (23.7)70.6 (20.8)47.2 (25.0)33.6 (22.9)22.8 (20.9)
Patient's global assessment of disease activity, mm68.0 (24.6)51.7 (27.4)43.3 (26.6)33.8 (23.3)65.5 (23.6)50.2 (25.4)42.7 (28.4)32.5 (24.8)66.1 (20.9)45.4 (25.3)33.3 (22.5)23.1 (19.2)
Physician's global assessment of disease activity, mm62.8 (23.5)45.8 (26.3)39.3 (26.4)30.5 (25.0)60.0 (23.7)41.7 (25.8)35.2 (25.7)28.1 (25.2)61.7 (23.0)37.3 (23.1)28.5 (21.8)18.9 (19.4)
TJC, n16.2 (8.3)11.9 (7.8)9.8 (8.0)7.1 (7.6)13.8 (7.2)9.9 (7.2)7.8 (7.3)4.9 (6.5)15.4 (8.2)9.8 (7.0)7.2 (6.3)4.0 (4.6)
SJC, n9.1 (6.0)5.5 (5.3)3.9 (4.7)2.8 (4.3)8.9 (6.1)5.9 (6.0)4.0 (5.3)2.4 (3.9)9.0 (6.6)4.2 (4.0)2.6 (2.9)1.4 (2.4)
ESR, mm/h54.0 (28.0)40.9 (27.8)34.4 (25.5)27.6 (23.9)45.1 (24.6)28.5 (20.0)26.8 (18.1)21.2 (16.2)52.7 (25.9)34.2 (22.6)24.6 (23.2)17.4 (18.0)
CRP, mg/L38.1 (40.3)25.3 (33.0)19.5 (30.7)15.2 (31.2)27.3 (25.0)12.9 (16.9)10.2 (13.6)9.4 (15.1)30.1 (28.7)12.8 (18.1)10.0 (19.6)7.8 (24.2)
HAQ1.53 (0.85)ND0.93 (0.83)0.76 (0.80)1.33 (0.92)ND0.84 (0.85)0.58 (0.74)1.43 (0.86)ND0.68 (0.78)0.45 (0.55)
SF-36237.8 (127.0)ND408.8 (186.1)504.5 (167.9)292.6 (155.3)ND463.0 (186.1)568.1 (142.4)279.1 (153.4)ND466.6 (169.2)545.4 (156.4)
DAS286.62 (1.31)5.55 (1.50)4.89 (1.56)4.03 (1.70)6.22 (1.28)5.02 (1.51)4.45 (1.72)3.57 (1.74)6.45 (1.36)5.03 (1.47)4.18 (1.54)3.19 (1.39)
  • Data are presented as mean (SD).

  • CRP, C-reactive protein; DAS28, 28-joint count Disease Activity Score 28; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; MTX, methotrexate; ND, not detected; SF-36, the 36-item Short-Form Health Survey questionnaire; SJC, swollen joint count; TJC, tender joint count; TwHF, Tripterygium wilfordii Hook F.